AI Article Synopsis

  • A mouse monoclonal antibody (MAb) developed through hybridoma technology targets a 150-kD surface antigen of Entamoeba histolytica, effectively blocking the microorganism's ability to adhere and cause damage to mammalian cells.
  • The genes for the antibody's light chain and part of the heavy chain were cloned into Escherichia coli for expression, using a plasmid designed specifically for producing Fab fragments with a hexa-histidine tag.
  • The resulting recombinant Fab fragments matched the specificity of the original MAb and notably inhibited the adherence of E. histolytica to red blood cells, demonstrating the efficiency of E. coli as an expression system for producing neutralizing antibodies.

Article Abstract

A mouse monoclonal antibody (MAb) (EH3015, IgG1 with a K light chain) prepared by hybridoma technology recognizes a 150-kD surface antigen of Entamoeba histolytica and inhibits adherence and cytotoxicity of the ameba to mammalian cells. The genes encoding the light chain and the Fd region of the heavy chain of the MAb were cloned and expressed in Escherichia coli. The plasmid used was designed for the expression of Fab with a hexa-histidine tag in the periplasmic space. Recombinant Fab fragments were purified and analyzed by an indirect immunofluorescence antibody test and Western immunoblot. The specificity of the recombinant Fab fragment was comparable with the parent whole IgG. In addition, the Fab fragments significantly inhibited the adherence of E. histolytica to erythrocytes. These results suggest that the production of a neutralizing MAb in Escherichia coli is practical and efficient with this expression system.

Download full-text PDF

Source
http://dx.doi.org/10.4269/ajtmh.1999.60.1.9988319DOI Listing

Publication Analysis

Top Keywords

mouse monoclonal
8
monoclonal antibody
8
fab fragment
8
surface antigen
8
antigen entamoeba
8
entamoeba histolytica
8
light chain
8
escherichia coli
8
recombinant fab
8
fab fragments
8

Similar Publications

Background: Chronic graft-versus-host disease (cGVHD) manifests with characteristics of autoimmune disease with organs attacked by pathogenic helper T cells. Recent studies have highlighted the role of T cells in cGVHD pathogenesis. Due to limited understanding of underlying mechanisms, preventing cGVHD after allogenic hematopoietic cell transplantation (HCT) has become a major challenge.

View Article and Find Full Text PDF

Monoclonal antibodies (mAbs) improve survival of patients with mature B-cell malignancies. Fcγ-receptor dependent effector mechanisms kill tumor cells but can promote antigen loss through trogocytosis, contributing to treatment failures. Cell-bound mAbs trigger the complement cascade to deposit C3 activation fragments and lyse cells.

View Article and Find Full Text PDF

Unlabelled: The emergence of novel variants of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to pose an ongoing challenge for global public health services, highlighting the urgent need for effective therapeutic interventions. Neutralizing monoclonal antibodies (mAbs) are a major therapeutic strategy for the treatment of COVID-19 and other viral diseases. In this study, we employed hybridoma technology to generate mAbs that target the BA.

View Article and Find Full Text PDF

Plague, caused by , poses a public health threat not only due to sporadic outbreaks across the globe but also due to its potential as a biothreat agent. Ironically, among the seven deadliest pandemics in global history, three were caused by . Pneumonic plague, the more contagious and severe form of the disease, is difficult to contain, requiring either prophylactic antibiotic treatment or vaccination.

View Article and Find Full Text PDF

Der p1 is one of the major allergens causing house dust mite (HDM) allergy. Pathological Der p1-specific B cells play a key role in allergic inflammation as producers of allergen-specific antibodies. Crosslinking the inhibitory FcγRIIb with the B cell receptor triggers a high-affinity suppressive signal in B cells.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!